Lundbeck en las noticias
Especializado en enfermedades cerebrales
Tamtam encontró 20 artículos recientes sobre Lundbeck.
- Barclays raises Lundbeck price target to 50 Danish kroner (48), reiterates equal weight - BN
- Cradle & Lundbeck: Partnering on Biotherapeutics and AI
- Ugens danske Vindere og tabere: Torm, Norden og Lundbeck topper
- Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress
- Lundbeck moves from rebuilding to “scaling phase”, Jefferies says
- Lundbeck vil præsentere præklinisk data om epilepsikandidat i weekenden
- AprilBio's APB-A1 Development Resumes at Lundbeck with Shift to Neurological Diseases; Licensing Deal Value Intact
- H. Lundbeck (CPSE:HLUN B) After Strong Q2 Results Is The Stock A Bargain Or Priced Right
- Eversana rolls out expanded AI agency platform with client Lundbeck going all-in
- Secret Novo-Lundbeck collaboration helped seal Swedish CNS deal: "You have to move quickly"
- H. Lundbeck (CPSE:HLUN A) - Analyse des actions
- Lundbeck expands AI partnership for commercialization in the US
- Lundbeck gains EU orphan status for anti‑ACTH antibody
- Lundbeck receives coveted status for drug candidate in the EU
- Lundbeck, Eversana Expand AI Commercialization Partnership
- Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
- Lundbeck And Eversana Announce Strategic Partnership
- Lundbeck and EVERSANA partner to advance AI-powered commercialization
- Lundbeck får eftertragtet status til lægemiddelkandidat i EU
- Lundbeck and EVERSANA Announce Strategic Partnership to Advance AI-Powered Commercialization
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como Lundbeck?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares